# DSB2455

Source: https://onco.cc/drugs/dsb2455/  
OnCo record `dsb2455` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DSB2455 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.

## Summary

The registry describes DSB2455 as a PARP1-selective inhibitor; the sponsor describes CNS activity. The linked registry records distinguish recruiting, closed, and discontinued studies; those states do not establish comparative efficacy or approval. The sponsor reports FDA Fast Track designation for HRR-altered TNBC brain metastases. Fast Track is a development designation, not marketing approval.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-10-06
- Modality: Small-molecule PARP1 inhibitor
- Mechanism: The registry describes DSB2455 as a PARP1-selective inhibitor; the sponsor describes CNS activity.

## Sources

- ClinicalTrials.gov NCT06458712: https://clinicaltrials.gov/study/NCT06458712
- Primary publication or sponsor source: https://dukestbio.com/duke-street-bio-fda-fast-track-dsb2455/

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [PARP](https://onco.cc/targets/parp/)
- trials: [Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies](https://onco.cc/trials/nct06458712/)

---
JSON: https://onco.cc/api/v1/entities/dsb2455.json